Hardly for the first time, a pundit following the company waxed bullish on its future.Viking Therapeutics (VKTX 1.94%), a biotech stock that has rocketed to prominence thanks to one of its investigational drugs, gave investors more reason to like it on Wednesday. The company's share price rose by almost 2% following an analyst's bullish new research note; that increase stood in positive contrast to the 0.2% decline of the S&P 500 index.Weight loss drug in the spotlightThe author of that note was Oppenheimer ...